Last reviewed · How we verify
Placebo extended-release oxycodone pills
A placebo formulation containing no active pharmaceutical ingredient, used as a control in clinical trials to measure the non-pharmacological effects of treatment.
A placebo formulation containing no active pharmaceutical ingredient, used as a control in clinical trials to measure the non-pharmacological effects of treatment. Used for Clinical trial control arm for oxycodone efficacy studies.
At a glance
| Generic name | Placebo extended-release oxycodone pills |
|---|---|
| Also known as | Placebo pill |
| Sponsor | University of Rochester |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Opioid Research |
| Phase | FDA-approved |
Mechanism of action
Placebo extended-release oxycodone pills are inert formulations designed to mimic the appearance and administration schedule of active oxycodone while containing no opioid or other therapeutic agent. They are used in randomized controlled trials to establish baseline efficacy attributable to expectation, ritual, and natural disease progression, allowing researchers to isolate the true pharmacological effects of the active drug.
Approved indications
- Clinical trial control arm for oxycodone efficacy studies
Common side effects
- Placebo response (pain relief, symptom improvement)
- Nocebo effects (adverse events attributed to inert substance)
Key clinical trials
- Dosing Intervals of Opioid Medication for Chronic Pain (PHASE4)
- Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin) (PHASE4)
- Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: